

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Francois HIRSCH et al.

Box SEQUENCE

Serial No. 09/856,796

GROUP Unknown

Filed May 25, 2001

Examiner Unknown

NF-KB ACTIVATION INHIBITORS,  
AND THEIR PHARMACEUTICAL USES

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §1.821-1.825

Commissioner for Patents

Washington, D.C. 20231

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. §1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 19 of the United States Code and that such willful false


HIRSCH et al. S.N. 09/856,796

statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

YOUNG & THOMPSON

By

  
Robert J. Patch

Attorney for Applicants

Registration No. 17,355

745 South 23rd Street

Arlington, VA 22202

Telephone: 521-2297

REG. NO.  
32,925

September 5, 2001